Legend Biotech Corporation
LEGN
$35.51
-$0.12-0.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 76.87% | 113.73% | 117.92% | 120.66% | 174.02% |
| Total Other Revenue | -89.71% | -12.57% | 3,395.53% | 1,740.61% | 1,458.18% |
| Total Revenue | 74.75% | 112.46% | 119.97% | 122.96% | 176.93% |
| Cost of Revenue | 17.22% | 18.53% | 23.12% | 23.55% | 23.53% |
| Gross Profit | 169.82% | 128.61% | 91.34% | 66.09% | 55.89% |
| SG&A Expenses | 35.44% | 38.55% | 41.48% | 37.94% | 26.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.34% | 24.11% | 28.19% | 27.58% | 24.42% |
| Operating Income | 41.66% | 45.40% | 31.00% | 21.90% | 25.61% |
| Income Before Tax | -6.00% | 57.80% | 69.60% | 32.13% | 45.97% |
| Income Tax Expenses | 1,125.35% | 1,140.46% | 1,113.57% | 844.17% | -383.68% |
| Earnings from Continuing Operations | -14.15% | 53.18% | 65.84% | 31.65% | 46.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.15% | 53.18% | 65.84% | 31.65% | 46.43% |
| EBIT | 41.66% | 45.40% | 31.00% | 21.90% | 25.61% |
| EBITDA | 42.47% | 46.50% | 32.09% | 22.77% | 26.48% |
| EPS Basic | -12.96% | 54.33% | 67.21% | 35.97% | 50.45% |
| Normalized Basic EPS | -2.91% | 59.99% | 71.56% | 36.46% | 50.03% |
| EPS Diluted | -12.86% | 54.40% | 67.27% | 36.04% | 50.49% |
| Normalized Diluted EPS | -4.30% | 59.14% | 70.82% | 36.46% | 50.03% |
| Average Basic Shares Outstanding | 0.90% | 1.71% | 3.88% | 6.21% | 9.08% |
| Average Diluted Shares Outstanding | 3.38% | 4.22% | 6.45% | 6.21% | 9.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |